Elsevier

Placenta

Volume 31, Issue 9, September 2010, Pages 803-810
Placenta

Effect of glucocorticoids on regulation of placental multidrug resistance phosphoglycoprotein (P-gp) in the mouse

https://doi.org/10.1016/j.placenta.2010.06.014Get rights and content

Abstract

Previously, we and others have shown that placental Abcb1 mRNA and phosphoglycoprotein (P-gp; encoded by Abcb1 mRNA) decreases over the second half of gestation, resulting in increased accumulation of P-gp substrates in the fetal compartment. Very little is known pertaining to the regulation of placental Abcb1 mRNA and P-gp. In non-placental adult murine tissues, synthetic glucocorticoids have been shown to regulate Abcb1 (Abcb1a and Abcb1b) mRNA in an isoform and tissue-specific manner. Furthermore, given that maternal and fetal endogenous glucocorticoid levels increase dramatically in late gestation, we hypothesized that synthetic glucocorticoids down-regulate placental Abcb1 and P-gp expression, consequently decreasing placental P-gp mediated fetal protection. Pregnant FVB mice were treated with dexamethasone (0.1 mg/kg or 1 mg/kg; s.c.) or vehicle (saline) from either embryonic day (E)9.5–15.5 or E12.5–E18.5 and then injected with [3H]digoxin (i.v.) to assess placental P-gp function. Dexamethasone treatment from E12.5–E18.5 significantly up-regulated Abcb1a mRNA (1 mg/kg) and P-gp (0.1 mg/kg and 1 mg/kg) expression on E18.5; however, this did not correlate to changes in drug accumulation in the fetal compartment. Similarly, dexamethasone (1 mg/kg) treatment during mid-gestation (E9.5–E15.5) significantly increased placental Abcb1a mRNA. In conclusion, glucocorticoids exhibit complex regulation of the P-gp transport system at the level of gene transcription and translation. Dexamethasone exposure up-regulates Abcb1a mRNA and P-gp protein, particularly in late gestation. However, these changes do not appear to be reflected by changes in P-gp mediated drug transfer. While the latter is somewhat reassuring with respect to antenatal use of glucocorticoids for management of preterm labour, further studies are required to understand regulation of these important drug transporters in the placenta.

Introduction

The multidrug resistance phosphoglycoprotein (P-gp; encoded by Abcb1 gene) was first discovered in multidrug resistant tumour cells, where it was shown to reduce cellular accumulation of chemotherapeutic agents [1]. Subsequently, murine multidrug resistance genes (Abcb1a and Abcb1b) were identified and together functionally resemble Abcb1 [2], [3], [4]. In addition to expression in cancer cells, P-gp is expressed in normal tissues where it serves an important role in limiting absorption and/or facilitating excretion of a wide range of substrates by actively transporting substrates from the inner to outer leaflet of the cell membrane [2], [3], [5], [6]. Tissues with specialized barrier functions such as the blood–brain, blood–testes and maternal–fetal barrier also express P-gp [7], [8], [9], [10], [11], although information in the human and murine pertaining to the regulation and functional significance of P-gp in these tissues is limited.

Solutes can cross the placenta by passive diffusion, occurring via a paracellular or transcellular route as well as via processes involving pinocytosis, filtration, facilitated diffusion and active transport [12], [13], [14]. Digoxin is a 780 MW lipophilic molecule which passively diffuses via the transcellular pathway [13]. Digoxin is a specific substrate for P-gp and once it has entered the plasma membrane lipid bilayer P-gp is activated to pump digoxin out of the cell [15], [16], [17]. However, depending on the concentration of digoxin and the presence of functional P-gp, some digoxin continues to diffuse across the syncitiotrophoblast, eventually entering fetal circulation. The functional importance of placental P-gp in limiting fetal digoxin accumulation has been verified on E15.5 with the use of Abcb1a/Abcb1b knockout mice [18].

In both the mouse and human, we and others have recently shown that placental P-gp, localized within the apical membrane of the syncitium, is highly expressed at mid-gestation but dramatically declines near term [8], [9], [19], corresponding to a significant increase in net transplacental transfer of [3H]digoxin (a robust pharmacological probe for assessing P-gp function) [20], [21]. Overall, this suggests a decrease in global protection provided by the placenta to the developing fetus with advancing gestation. Other studies in the mouse, have shown that P-gp plays a crucial role in preventing transplacental transfer of a number of exogenous substrates; thus protecting the developing fetus from their potential adverse effects [18], [21], [22]. Despite these dramatic changes in mouse and human placental P-gp expression and function in late gestation, little is known with regards to regulation. Steroids have previously been shown to regulate Abcb1 gene expression in other tissues in the rat and mouse. For example, progesterone and estrogen are important regulators of Abcb1 gene expression in uterine tissue [18], [23], [24], [25]. However, we have recently shown that progesterone at physiological concentrations does not appear to exert a regulatory role on mouse placental P-gp [20], a finding recently corroborated in the rat [26]. Maternal plasma glucocorticoid levels increase exponentially in late gestation in all mammals [27], [28], [29], [30], [31]. Further, placental sensitivity to glucocorticoids increases with advancing gestation [32], [33]. This increase coincides with the down-regulation of placental Abcb1a, Abcb1b mRNA and P-gp, suggesting a potential regulatory role [9]. Given the difference in placental sensitivity to glucocorticoids and the low levels of P-gp on E18.5, we predicted that glucocorticoid regulation of placental P-gp would change as a function of gestational age and that glucocorticoid effects may be limited near term. Synthetic glucocorticoids are administered to approximately 10% of all pregnant women during the management of threatened preterm labour [34]. This treatment is very effective in bringing about the premature maturation of the fetal lung [35], however, due to the difficulty in diagnosing preterm labour, many fetuses that go on to deliver at normal term are exposed to synthetic glucocorticoid [34].

Dexamethasone has been shown to regulate P-gp expression in other barrier tissues (blood–brain barrier) and in vitro [36], [37], [38], [39]. To date, there is virtually no information on the potential glucocorticoid regulation of placental P-gp, in vivo. A single study has investigated the regulatory role of dexamethasone on placental Abcb1 mRNA expression in the rat placenta [26]. However, in the rat, the ontogenic profile of placental Abcb1 mRNA and P-gp differs compared to that shown in the human and mouse placenta. Determining the regulation of placental P-gp would be valuable for the development of improved strategies for maternal and fetal therapies as well as improved fetal protection. In this study, we hypothesized that exposure to synthetic glucocorticoid (dexamethasone) will: 1) result in a down-regulation of both Abcb1 mRNA isoforms and P-gp within the placental barrier, 2) increase substrate accumulation in the fetal compartment and 3) that these regulatory effects are both gestational age and dose-dependent.

Section snippets

Materials and methods

Female FVB mice (Charles River, Germantown, NY) were bred in our colony. Pregnancy was defined after presence of vaginal plug and designated as E0.5 (average gestation period ∼ 19.5 days). All animals were identically housed and provided with standard chow ad libitum (Teklad 2018, Harlan Laboratories, Mississauga, Canada). These studies were performed using protocols approved by the Animal Care Committee at the University of Toronto and in accordance with the Canadian Council for Animal Care.

Effect of dexamethasone on placental and fetal weights

Daily injections of dexamethasone (1 mg/kg) during mid-gestation (E9.5–E15.5) resulted in a significant (P < 0.05) reduction in placental weight on E15.5 when compared to vehicle, while the lower dose of dexamethasone (0.1 mg/kg) did not significantly affect placental weight (Fig. 1A). Neither dose of dexamethasone significantly altered placental weight on embryonic day (E) 18.5 (Fig. 1B). One-Way ANOVA revealed profound effects of synthetic glucocorticoid exposure on fetal growth during

Discussion

The present study has, for the first time, examined the regulation of mouse placental Abcb1a and Abcb1b mRNA, P-gp protein expression and function in vivo by synthetic glucocorticoid. We have shown that synthetic glucocorticoid (dexamethasone) exposure alters placental Abcb1a mRNA expression during mid- and late gestation in an age-dependent manner. However, the effects of dexamethasone on Abcb1a mRNA and P-gp protein expression do not correlate with changes in placental P-gp mediated

Acknowledgements

This study was funded by the Canadian Institutes for Health Research (FRN-57746; to S.G.M. and W.G. and Doctoral Research Award to S.P.).

References (64)

  • O. Dammann et al.

    Glucocorticoid therapy in the fetus and newborn–Introduction

    Semin Neonatol

    (2001)
  • Y. Mizoguchi et al.

    Corticosterone is required for the prolactin receptor gene expression in the late pregnant mouse mammary gland

    Mol Cell Endocrinol

    (1997)
  • S.V. Koenen et al.

    Overexposure to antenatal corticosteroids: a global concern

    J Obstet Gynaecol Can

    (2007)
  • A. Kapoor et al.

    Fetal programming of hypothalamic-pituitary-adrenal (HPA) axis function and behavior by synthetic glucocorticoids

    Brain Res Rev

    (2008)
  • J.C. Cross et al.

    Genes, development and evolution of the placenta

    Placenta

    (2003)
  • P. Georgiades et al.

    Comparative developmental anatomy of the murine and human definitive placentae

    Placenta

    (2002)
  • K. Ueda et al.

    Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene

    J Biol Chem

    (1987)
  • B. Baisden et al.

    Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta

    Placenta

    (2007)
  • Q. Mei et al.

    Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2

    J Pharm Sci

    (2004)
  • P. Pavek et al.

    Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines

    Placenta

    (2007)
  • D. Cohen et al.

    Structural and functional analysis of the mouse mdr1b gene promoter

    J Biol Chem

    (1991)
  • M.M. Gottesman et al.

    P-glycoprotein and multidrug resistance

    Curr Opin Genet Dev

    (1996)
  • A.H. Schinkel et al.

    Multidrug-Resistance and the role of P-Glycoprotein knockout mice

    Eur J Cancer

    (1995)
  • F. Thiebaut et al.

    Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

    Proc Natl Acad Sci U S A

    (1987)
  • J.M. Croop et al.

    The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues

    Mol Cell Biol

    (1989)
  • M.M. Gottesman et al.

    Biochemistry of multidrug resistance mediated by the multidrug transporter

    Annu Rev Biochem

    (1993)
  • C. Cordon-Cardo et al.

    Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues

    J Histochem Cytochem

    (1990)
  • A. MacFarland et al.

    Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta

    Histochem J

    (1994)
  • G.M. Kalabis et al.

    Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection

    Biol Reprod

    (2005)
  • P. Myllynen et al.

    The fate and effects of xenobiotics in human placenta

    Expert Opin Drug Metab Toxicol

    (2007)
  • G.M. Pacifici et al.

    Placental transfer of drugs administered to the mother

    Clin Pharm

    (1995)
  • V. Ganapathy et al.

    Placental transporters relevant to drug distribution across the maternal-fetal interface

    J Pharmacol Exp Ther

    (2000)
  • Cited by (44)

    • P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

      2022, Heliyon
      Citation Excerpt :

      The transforming growth factor-beta 1 (TGF-β1)/Smad signalling pathway has also been recognised as a positive regulator of PGP [194], with studies showing TGF-β1 activity being mediated through both the ALK1 and ALK5 pathways [195]. TGF-β1 activity can also be modulated by glucocorticoids [196], which also possess the ability to regulate PGP expression levels directly [197, 198, 199, 200, 201]. The ABCB1 gene itself can also be modulated by epigenetic mechanisms, such as histone acetylation [194, 202, 203, 204].

    • Multidrug resistance p-glycoprotein (p-gp), glucocorticoids, and the stress response

      2019, Stress: Physiology, Biochemistry, and Pathology Handbook of Stress Series, Volume 3
    • Review: The blood-brain barrier; protecting the developing fetal brain

      2017, Placenta
      Citation Excerpt :

      This suggests a compensatory mechanism that ensures continual protection of the brain from xenobiotics that are no longer sufficiently repelled by the placenta [46]. The mechanism of this action is unclear, however it is known that P-gp expression at the BBB appears to be regulated by glucocorticoids and, that BBB P-gp levels rise with a simultaneous increase in maternal and fetal cortisol levels [47,48]. P-gp is involved in the transport of several prescription medications commonly administered to women during pregnancy to treat various conditions including asthma, hypertension, diabetes and epilepsy [49,50].

    • Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: Roles of P-glycoprotein and BCRP induction by rifampicin

      2016, Poultry Science
      Citation Excerpt :

      P-gp can modulate the pharmacokinetics of drugs resulting in drug-drug interactions of different compounds (Cox et al., 2002; Lin and Yamazaki, 2003; Endres et al., 2006). Strong evidence shows that expression and activity of P-gp can be inhibited or induced by dietary components, hormones, and several xenobiotics (Barnes, 2001; Kim and Benet, 2004; Petropoulos et al., 2010). BCRP also play an important role in drug interactions, as it is involved in drug absorption and disposition (Kruijtzer et al., 2002; Endres et al., 2006).

    • Pharmacokinetics of drugs in pregnancy

      2015, Seminars in Perinatology
      Citation Excerpt :

      Surprisingly, studies investigating a possible direct link demonstrate that prolonged exposure to dexamethasone increased P-gp and decreased BCRP expression in mice.57,58 By comparison, treatment of trophoblast cells with inflammatory cytokines or simulated infection in pregnant rats resulted in decreased P-gp and BCRP expression.59,60 Also, P-gp and BCRP expression is lower in preterm placentas and placentas from women with preeclampsia compared to term placentas from uncomplicated pregnancies, suggesting a role for hypoxia in mediating these transporters.57

    View all citing articles on Scopus
    View full text